View Future GrowthSam-A Pharm 과거 순이익 실적과거 기준 점검 2/6Sam-A Pharm은 연평균 25.6%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 12% 증가했습니다. 매출은 연평균 9%의 비율로 증가했습니다. Sam-A Pharm의 자기자본이익률은 3.9%이고 순이익률은 12.5%입니다.핵심 정보25.61%순이익 성장률25.60%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률11.32%매출 성장률8.97%자기자본이익률3.93%순이익률12.53%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트분석 기사 • Apr 01We Think That There Are More Issues For Sam-A Pharm (KOSDAQ:009300) Than Just Sluggish EarningsSam-A Pharm. Co., Ltd's ( KOSDAQ:009300 ) recent weak earnings report didn't cause a big stock movement. We think that...Reported Earnings • Nov 19Third quarter 2025 earnings released: ₩9.00 loss per share (vs ₩345 profit in 3Q 2024)Third quarter 2025 results: ₩9.00 loss per share (down from ₩345 profit in 3Q 2024). Revenue: ₩15.1b (down 28% from 3Q 2024). Net loss: ₩54.1m (down 103% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 20First quarter 2025 earnings released: EPS: ₩1,029 (vs ₩1,534 in 1Q 2024)First quarter 2025 results: EPS: ₩1,029 (down from ₩1,534 in 1Q 2024). Revenue: ₩24.5b (down 18% from 1Q 2024). Net income: ₩6.28b (down 33% from 1Q 2024). Profit margin: 26% (down from 31% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • May 18First quarter 2024 earnings released: EPS: ₩1,534 (vs ₩1,114 in 1Q 2023)First quarter 2024 results: EPS: ₩1,534 (up from ₩1,114 in 1Q 2023). Revenue: ₩30.0b (up 22% from 1Q 2023). Net income: ₩9.36b (up 38% from 1Q 2023). Profit margin: 31% (up from 28% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩668 (vs ₩676 in 3Q 2022)Third quarter 2023 results: EPS: ₩668 (down from ₩676 in 3Q 2022). Revenue: ₩22.1b (up 2.8% from 3Q 2022). Net income: ₩4.08b (down 1.2% from 3Q 2022). Profit margin: 18% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Reported Earnings • May 19First quarter 2023 earnings released: EPS: ₩1,114 (vs ₩521 in 1Q 2022)First quarter 2023 results: EPS: ₩1,114 (up from ₩521 in 1Q 2022). Revenue: ₩24.7b (up 28% from 1Q 2022). Net income: ₩6.80b (up 114% from 1Q 2022). Profit margin: 28% (up from 17% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.모든 업데이트 보기Recent updatesNew Risk • May 21New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 13% Last year net profit margin: 21% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (13% net profit margin). Market cap is less than US$100m (₩95.3b market cap, or US$63.3m).분석 기사 • Apr 01We Think That There Are More Issues For Sam-A Pharm (KOSDAQ:009300) Than Just Sluggish EarningsSam-A Pharm. Co., Ltd's ( KOSDAQ:009300 ) recent weak earnings report didn't cause a big stock movement. We think that...공시 • Feb 28Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 27, 2026Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: seminar room, 49, donghwagongdan-ro, munmak-eup, gangwon-do, wonju South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩800 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 28 April 2026. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 4.9%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).Reported Earnings • Nov 19Third quarter 2025 earnings released: ₩9.00 loss per share (vs ₩345 profit in 3Q 2024)Third quarter 2025 results: ₩9.00 loss per share (down from ₩345 profit in 3Q 2024). Revenue: ₩15.1b (down 28% from 3Q 2024). Net loss: ₩54.1m (down 103% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Declared Dividend • Nov 08Dividend of ₩800 announcedDividend of ₩800 is the same as last year. Ex-date: 29th December 2025 Payment date: 28th April 2026 Dividend yield will be 4.8%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is well covered by both earnings (32% earnings payout ratio) and cash flows (34% cash payout ratio). The dividend has increased by an average of 18% per year over the past 6 years and payments have been stable during that time. Earnings per share has grown by 21% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Nov 07Sam-A Pharm. Co., Ltd announces Annual dividend, payable on April 28, 2026Sam-A Pharm. Co., Ltd announced Annual dividend of KRW 800.0000 per share payable on April 28, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.Reported Earnings • May 20First quarter 2025 earnings released: EPS: ₩1,029 (vs ₩1,534 in 1Q 2024)First quarter 2025 results: EPS: ₩1,029 (down from ₩1,534 in 1Q 2024). Revenue: ₩24.5b (down 18% from 1Q 2024). Net income: ₩6.28b (down 33% from 1Q 2024). Profit margin: 26% (down from 31% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.공시 • Mar 01Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 28, 2025Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: seminar room, 49, donghwagongdan-ro, munmak-eup, gangwon-do, wonju South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩750 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 4.4%. Within top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).분석 기사 • Dec 06Take Care Before Jumping Onto Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Even Though It's 26% CheaperThe Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) share price has fared very poorly over the last month, falling by a...분석 기사 • Nov 13Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩130.9b market cap, or US$99.5m).New Risk • Sep 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩132.1b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩132.1b market cap, or US$99.0m).분석 기사 • Aug 25Earnings Working Against Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Share Price Following 34% DiveSam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) shares have retraced a considerable 34% in the last month, reversing a fair...Valuation Update With 7 Day Price Move • Aug 20Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩25,350, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 69% over the past three years.분석 기사 • Jul 11Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Price Is Right But Growth Is Lacking After Shares Rocket 32%Despite an already strong run, Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) shares have been powering on, with a gain of 32...Valuation Update With 7 Day Price Move • Jul 10Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩27,200, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 82% over the past three years.Buy Or Sell Opportunity • Jul 01Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 35% to ₩22,000. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.분석 기사 • Jun 21Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩22,500, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 47% over the past three years.Buy Or Sell Opportunity • Jun 20Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 36% to ₩22,500. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₩123.9b market cap, or US$89.7m).Buy Or Sell Opportunity • May 29Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 26% to ₩21,500. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.분석 기사 • May 25Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Shares Bounce 26% But Its Business Still Trails The MarketThe Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) share price has done very well over the last month, posting an excellent...Reported Earnings • May 18First quarter 2024 earnings released: EPS: ₩1,534 (vs ₩1,114 in 1Q 2023)First quarter 2024 results: EPS: ₩1,534 (up from ₩1,114 in 1Q 2023). Revenue: ₩30.0b (up 22% from 1Q 2023). Net income: ₩9.36b (up 38% from 1Q 2023). Profit margin: 31% (up from 28% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩19,150, the stock trades at a trailing P/E ratio of 5.5x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 32% over the past three years.Upcoming Dividend • Dec 20Upcoming dividend of ₩400 per share at 2.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 12 April 2024. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩668 (vs ₩676 in 3Q 2022)Third quarter 2023 results: EPS: ₩668 (down from ₩676 in 3Q 2022). Revenue: ₩22.1b (up 2.8% from 3Q 2022). Net income: ₩4.08b (down 1.2% from 3Q 2022). Profit margin: 18% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Reported Earnings • May 19First quarter 2023 earnings released: EPS: ₩1,114 (vs ₩521 in 1Q 2022)First quarter 2023 results: EPS: ₩1,114 (up from ₩521 in 1Q 2022). Revenue: ₩24.7b (up 28% from 1Q 2022). Net income: ₩6.80b (up 114% from 1Q 2022). Profit margin: 28% (up from 17% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Dec 21Upcoming dividend of ₩250 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 14 April 2023. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩18,550, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 22% over the past three years.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 02 May 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 1.6%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).분석 기사 • Apr 08Key Things To Consider Before Buying Sam-A Pharm. Co., Ltd (KOSDAQ:009300) For Its DividendToday we'll take a closer look at Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) from a dividend investor's perspective...Is New 90 Day High Low • Mar 10New 90-day low: ₩14,500The company is down 16% from its price of ₩17,350 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 23% over the same period.분석 기사 • Mar 04Is Sam-A Pharm (KOSDAQ:009300) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Jan 28How Much Did Sam-A Pharm's(KOSDAQ:009300) Shareholders Earn From Share Price Movements Over The Last Three Years?As an investor its worth striving to ensure your overall portfolio beats the market average. But in any portfolio...Is New 90 Day High Low • Jan 15New 90-day low: ₩15,600The company is down 10.0% from its price of ₩17,350 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 20% over the same period.분석 기사 • Dec 24Four Days Left To Buy Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Before The Ex-Dividend DateIt looks like Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) is about to go ex-dividend in the next 4 days. Investors can...분석 기사 • Dec 07Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Is Yielding 1.6% - But Is It A Buy?Is Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) a good dividend stock? How can we tell? Dividend paying companies with...Reported Earnings • Dec 03Third quarter 2020 earnings released: ₩111 loss per shareThe company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: ₩12.2b (down 26% from 3Q 2019). Net loss: ₩675.4m (down 135% from profit in 3Q 2019).Is New 90 Day High Low • Oct 22New 90-day low: ₩16,300The company is down 16% from its price of ₩19,500 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.매출 및 비용 세부 내역Sam-A Pharm가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A009300 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 2670,9288,88725,2846,87031 Dec 2577,79912,94026,5056,13630 Sep 2576,65913,18727,7215,00230 Jun 2582,51815,34427,2606,00831 Mar 2590,12619,00028,4685,24131 Dec 2495,58122,08028,3935,42130 Sep 24101,39322,76831,6405,09130 Jun 24102,55024,74429,9885,63731 Mar 24102,51123,93629,7396,10531 Dec 2397,21121,37429,0836,39830 Sep 2395,93120,33828,8256,43130 Jun 2395,32420,38727,7505,44131 Mar 2387,15915,53131,3901,45131 Dec 2281,70011,91226,6613,77130 Sep 2275,47911,02924,0362,97730 Jun 2266,1727,52022,5873,25831 Mar 2263,6387,00016,0247,60031 Dec 2154,6663,39220,8143,82930 Sep 2150,90717820,9693,77630 Jun 2150,870-1,11521,6904,12031 Mar 2148,548-1,65023,1022,84731 Dec 2053,65312422,7803,68130 Sep 2059,7753,39222,9774,16130 Jun 2064,0255,98625,1364,13331 Mar 2070,3469,12825,8244,84331 Dec 1971,56010,19726,1055,38630 Sep 1970,7159,80727,2205,72831 Dec 1866,9478,80126,2784,889양질의 수익: A009300는 고품질 수익을 보유하고 있습니다.이익 마진 증가: A009300의 현재 순 이익률 (12.5%)은 지난해 (21.1%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A009300는 지난 5년 동안 흑자전환하며 연평균 25.6%의 수익 성장을 기록했습니다.성장 가속화: A009300은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: A009300은 지난 1년 동안 수익이 감소(-53.2%)하여 Pharmaceuticals 업계 평균(25.5%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: A009300의 자본 수익률(3.9%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/12 19:50종가2026/06/12 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sam-A Pharm. Co., Ltd는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
분석 기사 • Apr 01We Think That There Are More Issues For Sam-A Pharm (KOSDAQ:009300) Than Just Sluggish EarningsSam-A Pharm. Co., Ltd's ( KOSDAQ:009300 ) recent weak earnings report didn't cause a big stock movement. We think that...
Reported Earnings • Nov 19Third quarter 2025 earnings released: ₩9.00 loss per share (vs ₩345 profit in 3Q 2024)Third quarter 2025 results: ₩9.00 loss per share (down from ₩345 profit in 3Q 2024). Revenue: ₩15.1b (down 28% from 3Q 2024). Net loss: ₩54.1m (down 103% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 20First quarter 2025 earnings released: EPS: ₩1,029 (vs ₩1,534 in 1Q 2024)First quarter 2025 results: EPS: ₩1,029 (down from ₩1,534 in 1Q 2024). Revenue: ₩24.5b (down 18% from 1Q 2024). Net income: ₩6.28b (down 33% from 1Q 2024). Profit margin: 26% (down from 31% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • May 18First quarter 2024 earnings released: EPS: ₩1,534 (vs ₩1,114 in 1Q 2023)First quarter 2024 results: EPS: ₩1,534 (up from ₩1,114 in 1Q 2023). Revenue: ₩30.0b (up 22% from 1Q 2023). Net income: ₩9.36b (up 38% from 1Q 2023). Profit margin: 31% (up from 28% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩668 (vs ₩676 in 3Q 2022)Third quarter 2023 results: EPS: ₩668 (down from ₩676 in 3Q 2022). Revenue: ₩22.1b (up 2.8% from 3Q 2022). Net income: ₩4.08b (down 1.2% from 3Q 2022). Profit margin: 18% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Reported Earnings • May 19First quarter 2023 earnings released: EPS: ₩1,114 (vs ₩521 in 1Q 2022)First quarter 2023 results: EPS: ₩1,114 (up from ₩521 in 1Q 2022). Revenue: ₩24.7b (up 28% from 1Q 2022). Net income: ₩6.80b (up 114% from 1Q 2022). Profit margin: 28% (up from 17% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
New Risk • May 21New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 13% Last year net profit margin: 21% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (13% net profit margin). Market cap is less than US$100m (₩95.3b market cap, or US$63.3m).
분석 기사 • Apr 01We Think That There Are More Issues For Sam-A Pharm (KOSDAQ:009300) Than Just Sluggish EarningsSam-A Pharm. Co., Ltd's ( KOSDAQ:009300 ) recent weak earnings report didn't cause a big stock movement. We think that...
공시 • Feb 28Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 27, 2026Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: seminar room, 49, donghwagongdan-ro, munmak-eup, gangwon-do, wonju South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩800 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 28 April 2026. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 4.9%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).
Reported Earnings • Nov 19Third quarter 2025 earnings released: ₩9.00 loss per share (vs ₩345 profit in 3Q 2024)Third quarter 2025 results: ₩9.00 loss per share (down from ₩345 profit in 3Q 2024). Revenue: ₩15.1b (down 28% from 3Q 2024). Net loss: ₩54.1m (down 103% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Declared Dividend • Nov 08Dividend of ₩800 announcedDividend of ₩800 is the same as last year. Ex-date: 29th December 2025 Payment date: 28th April 2026 Dividend yield will be 4.8%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is well covered by both earnings (32% earnings payout ratio) and cash flows (34% cash payout ratio). The dividend has increased by an average of 18% per year over the past 6 years and payments have been stable during that time. Earnings per share has grown by 21% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Nov 07Sam-A Pharm. Co., Ltd announces Annual dividend, payable on April 28, 2026Sam-A Pharm. Co., Ltd announced Annual dividend of KRW 800.0000 per share payable on April 28, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
Reported Earnings • May 20First quarter 2025 earnings released: EPS: ₩1,029 (vs ₩1,534 in 1Q 2024)First quarter 2025 results: EPS: ₩1,029 (down from ₩1,534 in 1Q 2024). Revenue: ₩24.5b (down 18% from 1Q 2024). Net income: ₩6.28b (down 33% from 1Q 2024). Profit margin: 26% (down from 31% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
공시 • Mar 01Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 28, 2025Sam-A Pharm. Co., Ltd, Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: seminar room, 49, donghwagongdan-ro, munmak-eup, gangwon-do, wonju South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩750 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 4.4%. Within top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).
분석 기사 • Dec 06Take Care Before Jumping Onto Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Even Though It's 26% CheaperThe Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) share price has fared very poorly over the last month, falling by a...
분석 기사 • Nov 13Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩130.9b market cap, or US$99.5m).
New Risk • Sep 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩132.1b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩132.1b market cap, or US$99.0m).
분석 기사 • Aug 25Earnings Working Against Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Share Price Following 34% DiveSam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) shares have retraced a considerable 34% in the last month, reversing a fair...
Valuation Update With 7 Day Price Move • Aug 20Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩25,350, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 69% over the past three years.
분석 기사 • Jul 11Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Price Is Right But Growth Is Lacking After Shares Rocket 32%Despite an already strong run, Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) shares have been powering on, with a gain of 32...
Valuation Update With 7 Day Price Move • Jul 10Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩27,200, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 82% over the past three years.
Buy Or Sell Opportunity • Jul 01Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 35% to ₩22,000. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.
분석 기사 • Jun 21Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩22,500, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 47% over the past three years.
Buy Or Sell Opportunity • Jun 20Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 36% to ₩22,500. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.
New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₩123.9b market cap, or US$89.7m).
Buy Or Sell Opportunity • May 29Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 26% to ₩21,500. The fair value is estimated to be ₩17,622, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.
분석 기사 • May 25Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Shares Bounce 26% But Its Business Still Trails The MarketThe Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) share price has done very well over the last month, posting an excellent...
Reported Earnings • May 18First quarter 2024 earnings released: EPS: ₩1,534 (vs ₩1,114 in 1Q 2023)First quarter 2024 results: EPS: ₩1,534 (up from ₩1,114 in 1Q 2023). Revenue: ₩30.0b (up 22% from 1Q 2023). Net income: ₩9.36b (up 38% from 1Q 2023). Profit margin: 31% (up from 28% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩19,150, the stock trades at a trailing P/E ratio of 5.5x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 32% over the past three years.
Upcoming Dividend • Dec 20Upcoming dividend of ₩400 per share at 2.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 12 April 2024. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩668 (vs ₩676 in 3Q 2022)Third quarter 2023 results: EPS: ₩668 (down from ₩676 in 3Q 2022). Revenue: ₩22.1b (up 2.8% from 3Q 2022). Net income: ₩4.08b (down 1.2% from 3Q 2022). Profit margin: 18% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Reported Earnings • May 19First quarter 2023 earnings released: EPS: ₩1,114 (vs ₩521 in 1Q 2022)First quarter 2023 results: EPS: ₩1,114 (up from ₩521 in 1Q 2022). Revenue: ₩24.7b (up 28% from 1Q 2022). Net income: ₩6.80b (up 114% from 1Q 2022). Profit margin: 28% (up from 17% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Dec 21Upcoming dividend of ₩250 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 14 April 2023. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩18,550, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 22% over the past three years.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 02 May 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 1.6%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).
분석 기사 • Apr 08Key Things To Consider Before Buying Sam-A Pharm. Co., Ltd (KOSDAQ:009300) For Its DividendToday we'll take a closer look at Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) from a dividend investor's perspective...
Is New 90 Day High Low • Mar 10New 90-day low: ₩14,500The company is down 16% from its price of ₩17,350 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 23% over the same period.
분석 기사 • Mar 04Is Sam-A Pharm (KOSDAQ:009300) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
분석 기사 • Jan 28How Much Did Sam-A Pharm's(KOSDAQ:009300) Shareholders Earn From Share Price Movements Over The Last Three Years?As an investor its worth striving to ensure your overall portfolio beats the market average. But in any portfolio...
Is New 90 Day High Low • Jan 15New 90-day low: ₩15,600The company is down 10.0% from its price of ₩17,350 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 20% over the same period.
분석 기사 • Dec 24Four Days Left To Buy Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Before The Ex-Dividend DateIt looks like Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) is about to go ex-dividend in the next 4 days. Investors can...
분석 기사 • Dec 07Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Is Yielding 1.6% - But Is It A Buy?Is Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) a good dividend stock? How can we tell? Dividend paying companies with...
Reported Earnings • Dec 03Third quarter 2020 earnings released: ₩111 loss per shareThe company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: ₩12.2b (down 26% from 3Q 2019). Net loss: ₩675.4m (down 135% from profit in 3Q 2019).
Is New 90 Day High Low • Oct 22New 90-day low: ₩16,300The company is down 16% from its price of ₩19,500 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.